PARSIPPANY, N.J., Nov. 14, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2012 Piper Jaffray Health Care Conference on Wednesday, November 28, 2012 at 11:00 am EST at the New York Palace Hotel in New York. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com. The webcast can also be accessed at the following URL: http://www.media-server.com/m/p/72m8826w
An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.
Watson is the world's third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Watson's global branded pharmaceutical business develops and markets products principally in Urology and Women's Health, and is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories. In addition, Watson is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.
For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.
CONTACTS: Investors: Lisa DeFrancesco (862) 261-7152
Media: Charlie Mayr (862) 261-8030
SOURCE Watson Pharmaceuticals, Inc.